WS
PHAS

Wedbush Securities’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

Wedbush Securities’s Portfolio PHAS Stock Details PHAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-13,865
Closed -$49K – 1021
2020
Q3 		$49K Buy
13,865
+2,465
+22% +$9.93K ﹤0.01% 885
2020
Q2 		$52K Buy
+11,400
New +$50.5K ﹤0.01% 903

Other funds holding PHAS

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Wedbush Securities's PHAS Position: Q4 2020 in Review

Wedbush Securities sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q4 2020, closing a stake of 13,865 shares — an estimated $49K sold.

Wedbush Securities first reported a position in PHAS in Q2 2020 and held it in 2 quarters. The position peaked at $52K in Q2 2020. 58 funds tracked by Wall St. Rank hold PHAS as of Q4 2020.

  • Wedbush Securities reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Wedbush Securities sold 13,865 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q4 2020, an estimated $49K.
  • Wedbush Securities first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q2 2020 and held it in 2 quarters.
  • Wedbush Securities's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $52K in Q2 2020.
  • 58 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q4 2020.

Based on Wedbush Securities's 13F filing for Q4 2020, filed 16 Feb 2021.